ADAP_OUT_1 [2025-04-02 13:38:58 -0400] 2707 Bytes | 729 tokens | Cum: 729 tkns (9.11% of 8k)
==========================================================================

We're scouting for winners today. Its 1:38:58 PM on Wed Apr 02, 2025 -0400 and I'm looking at Adaptimmune Therapeutics (ADAP) up to 0.299001 from 0.25

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: Adaptimmune Therapeutics (ADAP)
IPO: 2015-05-06 (9 Years Ago)
Market Cap: $72,590,854
Shares Outstanding: 1,543,390,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Here's the first list of news for Adaptimmune Therapeutics:

C1 - Mar-21-25 12:05PM - Earnings To Watch: Adaptimmune Therapeutics PLC (ADAP) Reports Q4 2024 Result
C2 - Mar-21-25 12:05PM 03:01AM - Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ...
C3 - Mar-20-25 12:10PM - Adaptimmune targets $400M sarcoma franchise peak sales by 2027
C4 - Mar-20-25 12:10PM 12:10PM - Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
C5 - Mar-20-25 12:10PM 07:00AM - Adaptimmune Provides Q4 and Full Year 2024 Business Update
C6 - Mar-19-25 06:00PM - Here's the major earnings before the open tomorrow
C7 - Mar-18-25 07:00AM - From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines
C8 - Mar-12-25 04:54PM - Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Adaptimmune Therapeutics (ADAP)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ADAP_OUT_3 [2025-04-02 13:39:01 -0400] 708 Bytes | 226 tokens | Cum: 957 tkns (11.96% of 8k)
==========================================================================

Showing C3 (chunk 1 of 1): C3:
**Adaptimmune targets $400M sarcoma franchise peak sales by 2027**
Date: Mar-20-25 12:10PM
Source: (SeekingAlpha)
URL: https://seekingalpha.com/news/4422937-adaptimmune-targets-400m-sarcoma-franchise-peak-sales-by-2027?utm_source=finviz.com&utm_medium=referral&feed_item_type=news

Error fetching article: 403 Client Error: Forbidden for url: https://seekingalpha.com/news/4422937-adaptimmune-targets-400m-sarcoma-franchise-peak-sales-by-2027?utm_source=finviz.com&utm_medium=referral&feed_item_type=news

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ADAP_OUT_5 [2025-04-02 13:39:02 -0400] 900 Bytes | 266 tokens | Cum: 1282 tkns (16.02% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T12:01:45Z - HC Wainwright Has Lowered Expectations for Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price...
A2 - 2025-04-01T13:01:01Z - What Analysts Are Saying About Adaptimmune Therapeutics Stock - Adaptimmune Therapeutics (NASDAQ:ADA...
A3 - 2025-03-30T06:09:08Z - Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by StockNews.com...
A4 - 2025-03-29T12:34:39Z - Analysts Set Expectations for ADAP Q1 Earnings...
A5 - 2025-03-28T10:00:47Z - Q1 Earnings Estimate for ADAP Issued By Zacks Small Cap...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ADAP_OUT_7 [2025-04-02 13:39:06 -0400] 1098 Bytes | 300 tokens | Cum: 1584 tkns (19.80% of 8k)
==========================================================================

Showing A1 (chunk 1 of 7): A1:
**HC Wainwright Has Lowered Expectations for Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price**Date: 2025-04-02Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/hc-wainwright-has-lowered-expectations-for-adaptimmune-therapeutics-nasdaqadap-stock-price-2025-04-01/Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) had its price objective reduced by equities research analysts at HC Wainwright from $3.50 to $3.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the biotechnology company's stock.

Several other research firms have also recently weighed in on ADAP. StockNews.com began coverage on Adaptimmune Therapeutics in a research note on Saturday. They set a "buy" rating for the company. Scotiabank reduced their price objective on shares of Adaptimmun

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ADAP_OUT_9 [2025-04-02 13:39:07 -0400] 1069 Bytes | 324 tokens | Cum: 2006 tkns (25.07% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-25T18:00:00Z - LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight
B2 - 2024-07-04T02:06:38Z - Biotechnology acquisitions could impact FDA decisions to watch in Q3 By Proactive Investors - Investing.com Australia
B3 - 2024-04-15T18:12:00Z - Adaptimmune (ADAP) Down on End of Collaboration With Roche
B4 - 2024-03-08T18:47:01Z - Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
B5 - 2024-03-08T15:08:32Z - Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
B6 - 2024-02-13T23:15:08Z - Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ADAP_OUT_11 [2025-04-02 13:39:11 -0400] 840 Bytes | 240 tokens | Cum: 2248 tkns (28.10% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/25/3032334/0/en/LAG-3-Immunotherapies-Market-Set-for-Rapid-Growth-in-the-Coming-10-Years-Across-the-7MM-as-Next-Generation-Therapies-Advance-DelveInsight.htmlThe LAG-3 next-generation therapies market is expected to grow significantly in the coming years due to the potential entry of major LAG-3 candidates, increase in incident cases of various solid tumors, and improvement in patient outcomes.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ADAP_OUT_13 [2025-04-02 13:39:12 -0400] 1094 Bytes | 278 tokens | Cum: 2610 tkns (32.62% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-24 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On March 24, 2025, Adaptimmune Therapeutics plc (the Company and collectively with any Company affiliates that are made party to the Loan Agrmt, Borrower) entered into an amendment (Amendment) to the Loan and Security Ag...

S2 - 2025-03-24 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our CONS financial statements and the related not...

S3 - 2025-03-20 8-K Item 2.02 Results of Oper and Fin Cond.

On March 20, 2025, Adaptimmune Therapeutics plc (the Company) provided a business update that included an update on its cash position at December 31, 2024.

The Companys preliminary estimated total liquidity was $151.6 m...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ADAP_OUT_15 [2025-04-02 13:39:16 -0400] 1098 Bytes | 261 tokens | Cum: 2873 tkns (35.91% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 1.01 Entry into a Material Definitive Agreement.

On March 24, 2025, Adaptimmune Therapeutics plc (the Company and collectively with any Company affiliates that are made party to the Loan Agreement, Borrower) entered into an amendment (Amendment) to the Loan and Security Agreement (the Loan Agreement) between the same Adaptimmune entities and with several banks and other financial institutions or entities from time to time party hereto as lenders (each, a Lender, and collectively Lenders) and Hercules Capital, Inc. Under the Amendment the Company agreed to make certain amendments to the reporting provisions in the Loan Agreement and to make a prepayment of $25.0 million of the loan amount under the Loan Agreement together with certain accrued interest up to the date of such pre-payment. The Company will also pay an end of term charge on such pre-paid amount of 5.85% as previous

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ADAP_OUT_17 [2025-04-02 13:39:27 -0400] 5887 Bytes | 1681 tokens | Cum: 4645 tkns (58.06% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+-------------------------+
| Volume: 4,448,092 | Perf Month: -38.79% | Option/Short: Yes / Yes | Sales Y/Y TTM: 194.23% |
+-------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 1.62M | Perf Quarter: -46.53% | Short Float: 2.49% | ROE: -273.36% |
+-------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 4.45 | Index: - | Short Ratio: 3.48 | ROI: -86.30% |
+-------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 37.97 | Market Cap: 75.82M | Short Interest: 5.64M | Sales Surprise: -61.53% |
+-------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.05 | Shs Outstand: 255.94M | Beta: 2.90 | EPS Surprise: -60.61% |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA20: -16.37% | Shs Float: 226.52M | Sales Q/Q: 1269.96% | P/E: - |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -38.96% | Inst Own: 37.39% | Sales past 5Y: 193.37% | Earnings: Mar 20 BMO |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -62.97% | Insider Own: 11.49% | Employees: 506 | |
+-------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: 28.78% | Insider Trans: -0.61% | Debt/Eq: 6.26 | |
+-------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Adaptimmune Therapeutics PLC (ADAP) by Bertrand William C JR (Chief Operating Officer) on 2025-02-20
- Option to purchase Ordinary Shares: 1612032 shares at $0 (D)
- Option to purchase Ordinary Shares: 1074696 shares at $0 (D)

Inside Trans: Adaptimmune Therapeutics PLC (ADAP) by Brewer Joanna Elizabeth (Chief Scientific Officer) on 2025-02-20
- Option to purchase Ordinary Shares: 1612032 shares at $0 (D)
- Option to purchase Ordinary Shares: 1074696 shares at $0 (D)

Inside Trans: Adaptimmune Therapeutics PLC (ADAP) by Lunger John (Chief Patient Supply Officer) on 2025-02-20
- Option to purchase Ordinary Shares: 1612032 shares at $0 (D)
- Option to purchase Ordinary Shares: 1074696 shares at $0 (D)

Inside Trans: Adaptimmune Therapeutics PLC (ADAP) by Piccina Cintia (Chief Commercial Officer) on 2025-02-20
- Option to purchase Ordinary Shares: 1612032 shares at $0 (D)
- Option to purchase Ordinary Shares: 1074696 shares at $0 (D)

Inside Trans: Adaptimmune Therapeutics PLC (ADAP) by Norry Elliot (Chief Medical Officer) on 2025-02-20
- Option to purchase Ordinary Shares: 1612032 shares at $0 (D)
- Option to purchase Ordinary Shares: 1074696 shares at $0 (D)

Inside Trans: Adaptimmune Therapeutics PLC (ADAP) by Rawcliffe Adrian (Chief Executive Officer) on 2025-02-20
- Option to purchase Ordinary Shares: 5143248 shares at $0 (D)
- Option to purchase Ordinary Shares: 3428832 shares at $0 (D)

Inside Trans: Adaptimmune Therapeutics PLC (ADAP) by Bertrand William C JR (Chief Operating Officer) on 2025-01-17
- American Depositary Shares representing Ordinary Shares: 5584 shares at $0.5808 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 178032000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -70814000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.289399
Average Volume: 2691445.09
30-Day High: 0.5107
30-Day Low: 0.197

[Detailed Financials: TTM 2024]
- Total Assets: $245,963,000.0
- Total Liabilities: $234,114,000.0
- Total Equity: $11,849,000.0
- Current Assets: $188,169,000.0
- Current Liabilities: $64,527,000.0

[Income Statement: TTM 2024]
- Revenue: $178,032,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.05

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-53,811,000.0

[Detailed Financials: FY 2024]
- Total Assets: $245,963,000.0
- Total Liabilities: $234,114,000.0
- Total Equity: $11,849,000.0
- Current Assets: $188,169,000.0
- Current Liabilities: $64,527,000.0

[Income Statement: FY 2024]
- Revenue: $178,032,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.05

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-53,811,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ADAP_OUT_19 [2025-04-02 13:39:29 -0400] 676 Bytes | 167 tokens | Cum: 5074 tkns (63.42% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ADAP_IN_21 [2025-04-02 13:39:29 -0400] 126 Bytes | 29 tokens | Cum: 5130 tkns (64.12% of 8k)
==========================================================================

====================================
[2025-04-02 13:39:29] # Analysis Completed
Elapsed Time: 31.39 seconds